Mehrul Hasnain
St. John's University
53 Papers
427 Citations
Mehrul Hasnain is an academic researcher from St. John's University. The author has contributed to research in topics: Medicine & Depression (differential diagnoses). The author has an hindex of 20, co-authored 52 publications. Previous affiliations of Mehrul Hasnain include Memorial University of Newfoundland & University of Pittsburgh.
Chat about Author
Papers
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder Section 3. Pharmacological Treatments
Sidney H. Kennedy,Raymond W. Lam,Roger S. McIntyre,S. Valérie Tourjman,Venkat Bhat,Pierre Blier,Mehrul Hasnain,Fabrice Jollant,Anthony J. Levitt,Glenda MacQueen,Shane McInerney,Diane McIntosh,Roumen Milev,Daniel J. Müller,Sagar V. Parikh,Norma L. Pearson,Arun V. Ravindran,Rudolf Uher +17 more
TL;DR: Evidence-based pharmacological treatments are available for first-line treatment of major depressive disorder and for management of inadequate response, however, given the limitations of the evidence base, pharmacological management of MDD still depends on tailoring treatments to the patient.
1K
QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
TL;DR: There is little evidence that drug-associated QTc interval prolongation by itself is sufficient to predict torsade de pointes (TdP) and future research needs to improve its precision and broaden its scope to better understand the factors that facilitate or attenuate progression of drug–QTc intervals prolongation to TdP.
147
Metabolic syndrome associated with schizophrenia and atypical antipsychotics.
TL;DR: This work provides an overview specifically addressing why patients with schizophrenia are at increased risk for metabolic problems, how commonly used antipsychotic medications vary in terms of their metabolic liability, and how to effectively screen for and monitor metabolic problems in patients receiving antipsychotics.
128
Citalopram, QTc Interval Prolongation, and Torsade de Pointes. How Should We Apply the Recent FDA Ruling?
W. Victor R. Vieweg,Mehrul Hasnain,Robert H Howland,John M. Hettema,Christopher Kogut,Mark A. Wood,Ananda K. Pandurangi +6 more
TL;DR: It is not believed current Phase 3 and Phase 4 studies provide sufficient information to limit current prescribing practices for citalopram, and drug manufacturers and regulatory agencies are urged to periodically publish full case reports of psychotropic drug-induced QTc interval prolongation, torsade de pointes, and sudden cardiac death.
109
Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports.
Jules C. Hancox,Mehrul Hasnain,W. Victor R. Vieweg,Ericka L. Breden Crouse,Adrian Baranchuk +4 more
- 28 Aug 2013
TL;DR: A systematic review of case reports sought to determine factors that link to azithromycin-induced/associated QTc interval prolongation and torsade de pointes and found 12 cases: seven female and five male.